Patnaik, A., Rosen, L.S., Tolaney, S.M., et al. (2014) Abstract CT232: Clinical Activity of LY2835219, a Novel Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Metastatic Breast Cancer. Cancer Research, 74, CT232-CT232.

靶向CDK6抗肿瘤小分子抑制剂的虚拟筛选
Virtual Screening of Antitumor Small Molecule Inhibitors Targeting CDK6

李树香, 王敏寿, 赵静峰, 王雁声, 徐高鑫    科研立项经费支持

药物化学Vol.11 No.3, 全文下载: PDF HTML XML DOI:10.12677/HJMCe.2023.113024, August 17 2023

68Ga-FAPI在乳腺癌诊断中的研究进展
Research Progress of 68Ga-FAPI in the Diagnosis of Breast Cancer

邓贵斌, 李义兴, 沈小兰, 刘德慧    科研立项经费支持

世界肿瘤研究Vol.14 No.1, 全文下载: PDF HTML XML DOI:10.12677/WJCR.2024.141004, January 18 2024

CDK4/6抑制剂治疗HR+/HER2?晚期乳腺癌的临床研究进展
Advances in Clinical Research on the CDK4/6 Inhibitors for HR+/HER2? Advanced Breast Cancer

李周娟, 赵久达   

临床医学进展Vol.14 No.3, 全文下载: PDF HTML XML DOI:10.12677/ACM.2024.143724, March 15 2024

天然活性成分抗乳腺癌的研究进展
Research Progress of Natural Active Ingredients against Breast Cancer

冉小娟, 余相地   

药物化学Vol.12 No.1, 全文下载: PDF HTML XML DOI:10.12677/HJMCe.2024.121009, February 28 2024

卡培他滨单药或联合方案治疗转移性乳腺癌临床疗效观察
Clinical Curative Effect Observation of the Treatment of Metastatic Breast Cancer (MBC) with Capecitabine Medicine or Combination Chemotherapy

李 杰, 李凤虎, 常建英, 李杰慧, 袁 佳, 刘诗苑, 冉 立    科研立项经费支持

临床医学进展Vol.4 No.4, 全文下载: PDF HTML DOI:10.12677/ACM.2014.44016, December 31 2014

CDK4/6抑制剂在HR+/HER-2−乳腺癌中耐药机制及生物标志物研究进展
Research Progress on Resistance Mechanism and Biomarker of CDK4/6 Inhibitor in HR+/HER-2− Breast Cancer

袁晓莉, 王振波   

临床医学进展Vol.11 No.12, 全文下载: PDF HTML XML DOI:10.12677/ACM.2021.1112851, December 16 2021